TACSTD2 and endometrioid adenocarcinoma: Because of the high TROP2 expression as well as the consistent engraftment of the primary END(K)265 tumor cell lines in SCID mice (27), the in vivo experiments comparing the antitumor activity of Dato-DXd, CTL-ADC, datopotamab, and control vehicle were performed using END(K)265 xenograft models (i.e., mixed endometrioid adenocarcinoma/clear cell).